Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. - Wikidata - awgldk - TriplyDB

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

http://www.wikidata.org/entity/Q42712758

about

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol Muscarinic antagonists in early stage clinical development for the treatment of asthma.Umeclidinium bromide and vilanterol trifenatate inhalation powder.Intracellular interactions of umeclidinium and vilanterol in human airway smooth muscle.The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.Umeclidinium/Vilanterol: first global approval.QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.Umeclidinium for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).Vilanterol trifenatate for the treatment of COPD.Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues.LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

P2860

Q24187438-68BFE1D4-1528-43F9-9DFF-AC6993BA56B0 Q26828602-88349765-8703-4C72-A945-BF54E8469099 Q30396144-B56EF3C8-091D-49F4-B876-0A4BAF91C1B3 Q33774769-B17811B3-C668-4CED-AC03-E39E5467EDE8 Q33884409-7F2DF72E-B51C-4AE5-9AA3-DFFC9B133D42 Q34368537-356A520A-8A33-49EC-86A6-7FF27C9007DB Q36787818-3ACDDC1C-34CE-443A-AF78-6C4F564DF9D1 Q38154255-1BE623BF-AFD1-49C6-8ABE-FFA751F79880 Q38188478-8BD92018-4CBD-4512-91AA-52A092A312E1 Q38194114-8186C7D5-8B00-4E59-9681-206AA8E68E88 Q38199533-ED35685B-1E23-4A65-A528-CEB1F7F2D081 Q38218619-2DB48DF9-9C8B-4D15-BAE7-C98C3F736E05 Q38258030-163996DD-6F4F-4C84-940C-D8FEECDD173F Q38259862-AB477F38-88A9-4184-8FEF-56535E95FC6E Q38266325-9BA97F88-F319-4F64-B6B2-9CDE1377131B Q38268349-0068F5E9-FC48-4822-A31E-01A48FC3DD0E Q38322792-9C36FACA-2036-4E65-9B56-406B2FAFBCA1 Q38692883-83D95418-8C23-4AAE-BD9F-A120E551D0EA Q38717900-B68E2D72-A363-4AE9-95F6-1DD21BB878CA Q38824916-FDB05532-2BDE-4BE1-9E20-28F368810A59 Q38854619-EFFFD6B2-305D-4B92-B05C-85D34946BADE Q39003291-7062ABAF-CB9C-4CAA-81DC-B4E03E1D2833 Q39297047-2B4F326F-589F-4CBC-A793-6A0F8424F00C Q55284121-602188E0-866A-4AF3-97AE-A124B942CD02 Q57483685-1BC4EE1C-DE44-4298-A548-1045C37A637D

P2860

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

http://www.wikidata.org/entity/Q42712758

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Pharmacological characterizati ...... eatment of pulmonary diseases.

@en

Pharmacological characterizati ...... eatment of pulmonary diseases.

@nl

type

label

Pharmacological characterizati ...... eatment of pulmonary diseases.

@en

Pharmacological characterizati ...... eatment of pulmonary diseases.

@nl

prefLabel

Pharmacological characterizati ...... eatment of pulmonary diseases.

@en

Pharmacological characterizati ...... eatment of pulmonary diseases.

@nl

P1433

Q42712758-8011C724-68A4-4349-BF60-D20E92F834AB

P1476

Q42712758-EC1DAD36-1D32-41C4-BE13-38E2A5913919

P2093

Q42712758-12B3B319-1B8B-4FA3-86E5-9B0E8FE1351C

Q42712758-16FE4B04-B4F9-43C5-9348-65035F852ECF

Q42712758-2107A59D-9C0F-4A7C-9955-583F1E9B8F69

Q42712758-27D7D985-D5D8-4493-8064-D3F245389F9B

Q42712758-305F23F6-5600-4559-BEC9-A99AE9F28CEE

Q42712758-41912346-EF8B-401A-8A09-D181E5742BFA

Q42712758-4A5B3873-FF0E-49ED-AD88-0C4636FCF190

Q42712758-561A23F9-093B-4827-AC2A-14179A3FBE56

Q42712758-5D469282-6E8D-48F6-9589-9703B08EC8C0

Q42712758-5D9FE6F8-6EBE-4A80-8F5F-35071AC41D7A

P304

Q42712758-62BA6B30-713E-4863-A4B9-78591A1C8D0E

P31

Q42712758-168A2786-7912-4E3C-9F94-799988285A95

P356

Q42712758-16078913-718A-4AF3-97B2-D544343D003D

P407

Q42712758-A5AB45AE-F7FB-47A0-952B-7DEC04BDA57F

P433

Q42712758-C5DAE78E-7CED-4B91-B16C-DD259C1A8DAE

P478

Q42712758-EDE9F37B-6AB8-43C3-B299-DFDCDF7B1E70

P577

Q42712758-9CC78D2F-A0C5-4409-8789-D19FDC6B915C

P5875

Q42712758-44E5AD7D-9C75-4820-8C45-3BD60C8A1253

P698

Q42712758-E1EF88EE-6C36-4DEB-9F8A-E3D6B5EB4BDB

P921

Q42712758-D7301725-3026-4737-AC1F-47C40E6CDBA8

P356

JPET.112.202051

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Pharmacological characterizati ...... eatment of pulmonary diseases.

@en

P2093

Charles J Kotzer

http://www.w3.org/2001/XMLSchema#string

Christopher J DeHaas

http://www.w3.org/2001/XMLSchema#string

Douglas W P Hay

http://www.w3.org/2001/XMLSchema#string

Dramane I Lainé

http://www.w3.org/2001/XMLSchema#string

Dulcie B Schmidt

http://www.w3.org/2001/XMLSchema#string

Edward F Webb

http://www.w3.org/2001/XMLSchema#string

Henry M Sarau

http://www.w3.org/2001/XMLSchema#string

James J Foley

http://www.w3.org/2001/XMLSchema#string

Mark A Luttmann

http://www.w3.org/2001/XMLSchema#string

Michael R Palovich

http://www.w3.org/2001/XMLSchema#string

P304

260-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.112.202051

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235716977

http://www.w3.org/2001/XMLSchema#string

P698

23435542

http://www.w3.org/2001/XMLSchema#string

P921